Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00386607 · ClinicalTrials.gov registry record · Phase 3
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 601
- Enrollment target
NCT00386607 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 601 participants.
The verdict
NCT00386607, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 601 participants
- Enrollment target
Study Summary
Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the combination of aliskiren/valsartan/Hydrochlorothiazide(HCTZ).
Interventions
- DRUG Valsartan
- DRUG Aliskiren
- DRUG Hydrochlorothiazide (HCTZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00386607
The ClinicalTrials.gov registry entry for NCT00386607 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 601 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Valsartan is the first listed.
NCT00386607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00386607 about?
NCT00386607 is a clinical study titled "A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.". Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the combination of aliskiren/valsartan/Hydrochlorothiazide(HCTZ).
What is the current status of trial NCT00386607?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 601 participants. The study started on 2006-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00386607?
The interventions under investigation include: Valsartan (DRUG), Aliskiren (DRUG), Hydrochlorothiazide (HCTZ) (DRUG).
Who is sponsoring clinical trial NCT00386607?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.